top of page


Exploring Carbon-Negative Biomanufacturing at Industrial Scale

A CO2 drawdown of 10 gigatonnes/year is an equivalent mass of carbon atoms as 63% of the carbon atoms present in all the crude oil the world produces annually. Gigatonne scale carbon capture should be viewed as the biggest global biomanufacturing opportunity in history.

Precision fermentation in E.Coli or yeast, has enabled the world to produce everything from vaccines and drugs (eg insulin) to materials (eg bioplastics). CyanoCapture is able to engineer cyanobacteria to produce desired compounds using CO2 and sunlight.

CyanoCapture in a funded partnership with the McCormick Lab at the University of Edinburgh, have jointly developed CRISPR libraries and Cre-lox systems that enable us to engineer fast-growing strains of cyanobacteria without antibiotic resistance markers.


CO2-to-palmitic acid (palm oil)

CyanoCapture has strains engineered to synthesise free fatty acids from CO2, of which 70% is a 16C palmitic acid - a major derivative of palm oil that is used in the cosmetics industry and in the chemicals industry for a broad range of applications.

De novo biosynthesis of high value recombinant proteins

With a 12-week turnaround, our strains can be engineered to heterologously express compounds of interest that may otherwise be hard-to-synthesise in traditional expression hosts, which can be grown at scale and extracted for biotech or pharmaceutical applications.


Overexpression of endogenous compounds including native proteins or phytohormones, grant cyanobacterial biomass potential medium-value use cases in agriculture as a biostimulant or in the aquaculture industry as a feedstock much higher in value than as a biofuel.

Explore Solutions

Carbon Negative Biomanufacturing


bottom of page